Shenzhen Chipscreen Biosciences Co. Ltd. Class ASSE: 688321

Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for Chiauranib Capsules for Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

· Issued by Shenzhen Chipscreen Biosciences Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for Chiauranib Capsules for Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis